Comparing CJC-1295, ipamorelin, and tesamorelin stack dosage? See typical research ranges, FDA status, timing, and safety notes in one guide.
There is no single official dosage for a CJC-1295, ipamorelin, and tesamorelin stack because only tesamorelin is FDA-approved, and no regulator has cleared these three peptides for combined use. In research and community discussions, dosages are listed separately for each compound — commonly 100–300 mcg of CJC-1295, 100–300 mcg of ipamorelin, and 1–2 mg of tesamorelin per day — rather than as one blended number. Anyone weighing a real-world protocol should review it with a licensed healthcare professional rather than rely on forum posts or product labels.
Why There Is No Single Stack Dosage
Each peptide has its own half-life, receptor target, and regulatory status, so a combined "stack dose" is really three separate doses delivered in the same overall protocol. Anyone comparing a cjc 1295 ipamorelin tesamorelin stack should start with that framework.
CJC-1295 and tesamorelin are both growth hormone-releasing hormone (GHRH) analogs, while ipamorelin is a ghrelin-receptor agonist that works through a different pathway. Because two of the three act on the same receptor, the combination is not simply additive. Tesamorelin and CJC-1295 both act on GHRH receptors, so stacking them does not introduce a new mechanism of action.
Typical Research Dosages at a Glance
The table below summarizes dose ranges that appear most often in published studies and user-reported protocols. These figures describe research or off-label use, not an approved regimen for the trio.
| Peptide | Common research dose range | Typical frequency | FDA status (US) |
|---|---|---|---|
| CJC-1295 with DAC | 1–2 mg per week | 1–2 injections weekly | Not FDA-approved for human use |
| CJC-1295 without DAC (mod GRF 1-29) | 100–300 mcg per injection | 1–3 times daily | Not FDA-approved for human use |
| Ipamorelin | 100–300 mcg per injection | 1–3 times daily, often before bed | Not FDA-approved for human use |
| Tesamorelin | 1–2 mg (FDA label: 2 mg) | Once daily, subcutaneous | FDA-approved as Egrifta for HIV-associated lipodystrophy |
The most frequently cited cjc-1295 ipamorelin dosage is 100 mcg of each per injection, typically once or twice daily. Higher amounts appear in community logs but are not supported by controlled trials of the three-peptide combination.
How Combined Protocols Are Usually Structured
Because CJC-1295 and tesamorelin share a receptor, most discussion of a tesamorelin and cjc-1295 stack centers on whether one should replace the other rather than be run together. A frequent question is how cjc-1295 ipamorelin vs tesamorelin compare in half-life and IGF-1 response.
- CJC-1295 with DAC has a long half-life of roughly 5–8 days, so it is typically dosed once or twice weekly.
- Tesamorelin has a short half-life of about 26–38 minutes and is dosed once daily.
- Ipamorelin has a half-life of roughly 2 hours and is often dosed 1–3 times daily.
- Most reported stacks pair CJC-1295 (without DAC) with ipamorelin and treat tesamorelin as an alternative, not an addition.
Timing, Cycle Length, and Injection Basics
Injection timing is usually tied to the body's natural growth hormone pulses. Common approaches include dosing before bed or after training, and avoiding food for 30 to 60 minutes around an injection.
Cycle length is not standardized. Community protocols often run 8 to 12 weeks followed by a break, while the FDA label for tesamorelin describes continuous daily use for HIV-associated lipodystrophy under medical supervision.
Some people reference a cjc 1295 ipamorelin 10mg dosage when reading vial labels, but 10 mg usually describes the total peptide in the vial, not the amount injected per dose. Online calculators that ask for body weight and sex can produce very different outputs, and most are not validated for clinical decision-making.
Safety, Side Effects, and Legal Status
None of these peptides should be treated as a cure or a casual supplement. Reported side effects in research and user accounts include injection-site reactions, water retention, joint discomfort, numbness or tingling in the hands, fatigue, and shifts in blood sugar.
Tesamorelin raises IGF-1 levels and carries FDA warnings about potential growth of existing tumors, increased blood sugar, and injection-site reactions. People with cancer, diabetes, or pituitary disease are generally advised to avoid growth-hormone-related peptides without medical supervision.
The U.S. Food and Drug Administration has approved tesamorelin only for HIV-associated lipodystrophy, not for bodybuilding or general fat loss. CJC-1295 and ipamorelin are sold as research chemicals and are not FDA-approved for human use in the United States.
Because these products are often purchased from unregulated suppliers, purity and actual peptide content can vary widely between vials. That variability makes any reported dosage hard to interpret or reproduce.
Bottom Line on the Three-Peptide Stack
There is no validated three-peptide stack dosage. The most defensible reading of the available information is that CJC-1295 and ipamorelin are usually discussed as a pair, while tesamorelin is usually discussed as a stand-alone, FDA-approved alternative for a specific medical condition.
Anyone considering these compounds should talk with a licensed healthcare provider first and should not treat forum discussions, vendor pages, or online calculators as medical guidance.
RELATED PEPTIDE TOPICCJC-1295 researchFrequently Asked Questions
What is the typical CJC-1295 and ipamorelin dosage?
Most published and community protocols cite 100–300 mcg of CJC-1295 and 100–300 mcg of ipamorelin per injection, given one to three times daily. CJC-1295 with DAC is instead dosed at 1–2 mg per week because of its longer half-life. No regulatory agency has approved either peptide for human use, so no officially recognized dosage exists.
Can you stack tesamorelin with CJC-1295 and ipamorelin?
Tesamorelin and CJC-1295 are both GHRH analogs that act on the same receptor, so combining them does not add a new mechanism. Ipamorelin works through a separate ghrelin-receptor pathway and is the more logical pairing with either GHRH analog. No clinical trial has evaluated the three-peptide combination in humans.
Is tesamorelin FDA-approved?
Yes. Tesamorelin is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss, bodybuilding, or anti-aging use. CJC-1295 and ipamorelin are not FDA-approved for any human indication.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.